In Brief
This article was originally published in The Tan Sheet
Executive Summary
Perrigo ships generic Mucinex extended-release; Valeant buys Obagi Medical Products; FDA advisory committee will discuss AERs; DXM legislation offered again; bill revived to allow Primatene Mist sales; Intercore will market MeliaLife products; more news In Brief.
You may also be interested in...
FDA Needs To Track Actions Built On Supplement AERs – GAO Report
A GAO report says FDA “may be able to expand” its use of supplement adverse event reports if it can track its use of the data to support actions it takes to protect consumers. The report makes five key recommendations for the agency to improve its approach to AERs.
In Brief
Plan B One-Step gets generic competition; legislation to restrict DXM introduced again; J&J agrees to reforms in settlement; China recants on MJN formula concerns; Buster line drives Hi-Tech Pharmacal OTC growth; Sabinsa awarded profits from infringed ForsLean trademark; more news In Brief.
Perrigo Sets Generic Mucinex Launch After Patent Claim Decision
The private labeler clears a Reckitt Benckiser legal hurdle and will launch generic Mucinex (guaifenesin) by April. Watson has filed ANDAs for three Mucinex products and could be a good strategic partner for Perrigo, an analyst suggests.